
    
      This is a multicenter, double-blind, randomized, placebo-controlled, 6-arm study to
      investigate the optimal dose regimen, efficacy, and safety of cysteamine in the treatment of
      adult patients with CF who are experiencing an exacerbation of CF-associated lung disease.
      Patients will be screened for the study and eligible patients will be randomized to receive
      either cysteamine or placebo as add-on therapy to their standard of care treatment for
      CF-associated lung disease.
    
  